Quick Answer
BioXcel Therapeutics, Inc. reported Cash and Equivalents of $28.41 million for fiscal year 2025.
BioXcel Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $28.41M | -4.8% |
| 2024 | $29.85M | -54.2% |
| 2023 | $65.22M | -66.3% |
| 2022 | $193.72M | -16.8% |
| 2021 | $232.97M | +9.3% |
| 2020 | $213.12M | +557.2% |
| 2019 | $32.43M | -23.8% |
| 2018 | $42.56M | +4698.8% |
| 2017 | $887.0K | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $36.18M | -10.4% | +107.5% |
| June 30, 2025 | $17.43M | -69.0% | -43.8% |
| March 31, 2025 | $31.01M | -58.2% | +3.9% |
| December 31, 2024 | $29.85M | -54.2% | -26.1% |
| September 30, 2024 | $40.39M | -55.1% | -28.2% |
| June 30, 2024 | $56.27M | -55.9% | -24.1% |
| March 31, 2024 | $74.14M | -55.2% | +13.7% |
| December 31, 2023 | $65.22M | -66.3% | -27.5% |
- BioXcel Therapeutics, Inc. showed a decrease of -4.8% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2017–2025 period, BioXcel Therapeutics, Inc.’s cash and equivalents has grown by 3103.5% (from $887.0 thousand to $28.41 million).
- The most recent figure is from BioXcel Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: